← Back to Search

Rho-Kinase Inhibitor

Rho-Kinase Inhibitor for Advanced Glaucoma

Phase 2

Waitlist Available

Research Sponsored by New York Glaucoma Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with open-angle glaucoma with prior glaucoma filtering surgery

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial will evaluate the efficacy of AR-12286 in delaying or avoiding the necessity of further surgical intervention in glaucoma patients with failed prior glaucoma filtering surgery and uncontrolled IOP.

Who is the study for?

This trial is for adults over 18 with advanced glaucoma who've had unsuccessful surgery to lower eye pressure and are at risk of more surgery. They must be able to attend treatment for 6 months, have high eye pressure or worsening vision, and not use other eye meds except for specific exceptions.Check my eligibility

What is being tested?

The study tests two strengths (0.5% and 0.7%) of a Rho-Kinase Inhibitor eyedrop, AR-12286, on patients with uncontrolled glaucoma after previous surgeries failed. It aims to see if the drops can reduce eye pressure effectively over six months and possibly delay or avoid further surgery.See study design

What are the potential side effects?

Possible side effects may include reactions at the application site like discomfort or redness, potential allergic reactions if sensitive to ingredients in the solution such as benzalkonium chloride, and general ocular irritation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have open-angle glaucoma and had surgery to lower eye pressure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Effect of study drug to reduce IOP

Secondary outcome measures

IOP Reduction

Trial Design

2Treatment groups

Experimental Treatment

Group I: 0.7% Rho-Kinase InhibitorExperimental Treatment1 Intervention

AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.

Group II: 0.5% Rho-Kinase InhibitorExperimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

New York Glaucoma Research InstituteLead Sponsor

2 Previous Clinical Trials

20 Total Patients Enrolled

2 Trials studying Glaucoma

20 Patients Enrolled for Glaucoma

Media Library

AR-12286 (Rho-Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02173223 — Phase 2

AR-12286 (Rho-Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02173223 — Phase 2

Glaucoma Research Study Groups: 0.7% Rho-Kinase Inhibitor, 0.5% Rho-Kinase Inhibitor

Glaucoma Clinical Trial 2023: AR-12286 Highlights & Side Effects. Trial Name: NCT02173223 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the potential risks associated with taking Rho-Kinase Inhibitor medication?

"While there is limited data to support the efficacy of Rho-Kinase Inhibitor, what evidence does exist suggests that it is safe. Consequently, our team has given it a 2."

Answered by AI

Are there any current openings for people who wish to participate in this clinical trial?

"According to the most recent information available on clinicaltrials.gov, this study is not currently seeking patients for participation. This particular trial was first posted on 6/1/2014 and received its last update on 4/23/2015; however, there are 205 other trials that might be a match for individuals looking for medical studies in which to participate."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt

Jessica Jasien 2014. "A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02173223.

All > Glaucoma